DFMO Rises Again
Combo Drug's Phase III Trial Aims to Prevent Colon Cancer
By Randy Osborne
Friday, April 19, 2013
Cancer Prevention Pharmaceuticals Inc. (CPP) is trying out its tumor-blocking approach in colon adenomas by way of a Phase III trial in a collaborative effort with the National Cancer Institute (NCI) that will enroll 1,340 survivors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.